PubRank
Search
About
Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Men With Hormone-refractory Prostate Cancer
Clinical Trial ID NCT00321620
PubWeight™ 32.31
‹?›
🔗 Visit the ClinicalTrials.gov page for NCT00321620
Top papers
Rank
Title
Journal
Year
PubWeight™
‹?›
1
Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study.
Lancet
2011
11.28
2
Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials.
Eur J Cancer
2012
4.29
3
Bone metastasis in prostate cancer: emerging therapeutic strategies.
Nat Rev Clin Oncol
2011
2.20
4
NCCN Task Force Report: Bone Health in Cancer Care.
J Natl Compr Canc Netw
2009
1.97
5
Bone-related Parameters are the Main Prognostic Factors for Overall Survival in Men with Bone Metastases from Castration-resistant Prostate Cancer.
Eur Urol
2014
1.81
6
Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events.
Ann Oncol
2014
1.71
7
Steps in prostate cancer progression that lead to bone metastasis.
Int J Cancer
2011
1.34
8
Future directions of bone-targeted therapy for metastatic breast cancer.
Nat Rev Clin Oncol
2010
1.27
9
Pain and health-related quality of life in patients with advanced solid tumours and bone metastases: integrated results from three randomized, double-blind studies of denosumab and zoledronic acid.
Support Care Cancer
2013
1.12
10
Novel targeted therapeutics for metastatic castration-resistant prostate cancer.
Cancer Lett
2009
1.04
11
The role of RANK-ligand inhibition in cancer: the story of denosumab.
Oncologist
2011
1.03
12
The science and practice of bone health in oncology: managing bone loss and metastasis in patients with solid tumors.
J Natl Compr Canc Netw
2009
1.03
13
Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer.
Support Care Cancer
2015
0.99
14
Hypocalcaemia in patients with metastatic bone disease treated with denosumab.
Eur J Cancer
2015
0.84
15
Cost per patient and potential budget implications of denosumab compared with zoledronic acid in adults with bone metastases from solid tumours who are at risk of skeletal-related events: an analysis for Austria, Sweden and Switzerland.
Eur J Hosp Pharm Sci Pract
2013
0.84
16
Emerging targeted therapies for castration-resistant prostate cancer.
Front Endocrinol (Lausanne)
2012
0.81
17
Denosumab for the treatment of bone metastases in breast cancer: evidence and opinion.
Ther Adv Med Oncol
2011
0.79
18
Prognostic and predictive value of plasma testosterone levels in patients receiving first-line chemotherapy for metastatic castrate-resistant prostate cancer.
Br J Cancer
2014
0.77
19
Expanding horizons in metastatic prostate cancer treatment.
Nat Rev Clin Oncol
2011
0.75
Next 100